Last reviewed · How we verify
Influenza vaccine GSK2340272A
Influenza vaccine GSK2340272A is a Influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Influenza prevention.
GSK2340272A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens.
GSK2340272A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens. Used for Influenza prevention.
At a glance
| Generic name | Influenza vaccine GSK2340272A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an influenza vaccine candidate, GSK2340272A works by presenting influenza viral antigens to the immune system to generate protective antibody and T-cell responses. This approach aims to prevent infection or reduce severity of influenza illness by priming the adaptive immune system to recognize and respond to circulating influenza strains. The specific formulation and adjuvant strategy of GSK2340272A are proprietary to GlaxoSmithKline's vaccine development program.
Approved indications
- Influenza prevention
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Systemic reactions (fever, myalgia, fatigue)
- Headache
Key clinical trials
- Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE3)
- Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children (PHASE3)
- Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults (PHASE3)
- Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults (PHASE3)
- Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A) (PHASE2)
- Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children (PHASE2)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccine GSK2340272A CI brief — competitive landscape report
- Influenza vaccine GSK2340272A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Influenza vaccine GSK2340272A
What is Influenza vaccine GSK2340272A?
How does Influenza vaccine GSK2340272A work?
What is Influenza vaccine GSK2340272A used for?
Who makes Influenza vaccine GSK2340272A?
What drug class is Influenza vaccine GSK2340272A in?
What development phase is Influenza vaccine GSK2340272A in?
What are the side effects of Influenza vaccine GSK2340272A?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Influenza prevention
- Compare: Influenza vaccine GSK2340272A vs similar drugs
- Pricing: Influenza vaccine GSK2340272A cost, discount & access